- In May 2024, AstraZeneca plc expanded access to its next-generation oral antiplatelet therapy, Brilinta (ticagrelor), in emerging markets including Southeast Asia and Latin America. This strategic move aims to reduce secondary cardiovascular events in post-AMI patients, aligning with global healthcare objectives focused on improving outcomes in high-risk populations. The initiative showcases AstraZeneca’s commitment to equitable access to life-saving therapies and its continued leadership in cardiovascular innovation
- In April 2024, Novartis AG announced positive real-world outcomes from its ENTRESTO (sacubitril/valsartan) therapy used in post-AMI patients with reduced ejection fraction. The data, presented at the American College of Cardiology Annual Scientific Session, demonstrated significant reductions in hospital readmission rates and cardiovascular mortality. This advancement reinforces Novartis’ focus on data-backed, guideline-driven care and its position at the forefront of RAAS inhibition in cardiac recovery
- In February 2024, Pfizer Inc. partnered with health systems in the U.S. and Canada to pilot a digital patient engagement platform tailored for post-AMI patients. The platform integrates medication reminders, tele-rehabilitation, and real-time health tracking to enhance patient adherence and recovery. This initiative reflects the growing importance of digital therapeutics in cardiac care and Pfizer’s ongoing investment in patient-centered innovation
- In January 2024, Bayer AG launched a new initiative across Europe promoting dual antiplatelet therapy (DAPT) best practices in early-stage myocardial infarction recovery. The campaign includes physician education, digital health tools, and updated prescribing guidelines for its widely used antiplatelet agent, Xarelto. This development aligns with Bayer’s broader cardiovascular strategy to reduce complications and mortality in the immediate post-AMI period
- In December 2023, Abbott Laboratories unveiled the expansion of its Remote Cardiac Monitoring Solutions to include post-AMI management tools, integrating wearables and AI-driven alerts for early identification of complications such as arrhythmias or reinfarction risk. This technological advancement empowers clinicians with real-time decision support, enhancing both acute and long-term post-infarction care. The move underscores Abbott’s leadership in connected health ecosystems and precision cardiac monitoring
